Central Fever Management

Definition and Diagnosis

• Central fever is defined as core temperature >37.5°C driven by neurological dysregulation without evidence of sepsis or clinically significant inflammatory processes, and is a diagnosis of exclusion that should be considered only after infectious and other non-infectious causes have been ruled out, particularly in patients with central nervous system disorders 1
• Key characteristics of central fever include persistent temperature elevations without a cyclic pattern 1

Diagnostic Approach

• A thorough workup should be performed before diagnosing central fever, including a chest radiograph, which is recommended for all ICU patients with new fever 2, 3, 4
• Blood cultures, at least two sets, 60 mL total, should be collected 2, 3
• If a central venous catheter is present, simultaneous collection of central and peripheral blood cultures should be performed 2, 3
• Consider CT imaging for patients with recent thoracic, abdominal, or pelvic surgery 2, 3
• For patients with neurological symptoms, consider lumbar puncture if not contraindicated 5

Treatment Options

• For patients who desire symptomatic relief, antipyretic medications are recommended over non-pharmacologic cooling methods 4, 6
• Routine use of antipyretics solely for temperature reduction is not recommended in critically ill patients 4, 6
• Fever management reduced body temperature but did not improve 28-day mortality, hospital mortality, or shock reversal in non-neurocritically ill patients 4, 6
• Uncontrolled neurogenic fever can precipitate secondary brain injury in patients with neurological conditions 1
• For patients with acute ischemic stroke, prompt fever treatment is recommended to prevent worse outcomes 7

Monitoring and Follow-up

• Use central temperature monitoring methods when available, such as pulmonary artery catheters, bladder catheters, or esophageal thermistors 8, 9
• When central monitoring is unavailable, oral or rectal temperatures are preferred over less reliable methods like axillary or tympanic measurements 8, 9
• Monitor for other signs of infection despite normal temperature, as certain patient populations may have blunted fever responses 9
• Elderly patients and those on immunosuppressive medications may not mount typical fever responses 9

Neurogenic Fever Causes and Mechanisms

Pathophysiological Mechanism

• Neurogenic fever is caused by neurological dysregulation of temperature control mechanisms, specifically from damage to the hypothalamus and its thermoregulatory pathways, occurring in the absence of infection or inflammatory processes, as stated by the American College of Critical Care Medicine 10, 11

Specific Neurological Injuries That Cause Neurogenic Fever

• Traumatic brain injury (TBI) is the most common cause of neurogenic fever, particularly with injuries affecting specific brain regions, according to the American College of Critical Care Medicine 10, 11
• Ischemic stroke affecting temperature-regulating regions can also cause neurogenic fever, as reported by the American Heart Association 12 and the American Stroke Association 13

Distinguishing Features from Other Fever Types

• Neurogenic fever has specific characteristics that differentiate it from infectious or inflammatory causes, including core temperature >37.5°C without evidence of sepsis or clinically significant inflammatory processes, as stated by the American College of Critical Care Medicine 10, 11

Incidence and Clinical Context

• Neurogenic fever is relatively common in traumatic brain injury, occurring in 4-37% of TBI survivors, and is more prevalent than historically recognized, according to the American College of Critical Care Medicine 10, 11

Mechanism of Secondary Brain Injury

• Once neurogenic fever develops, it causes harm through multiple mechanisms, including increased metabolic demands on already-injured brain tissue, enhanced release of excitatory neurotransmitters, and increased free radical production, as reported by the American Heart Association 12 and the American Stroke Association 13
• Elevated intracranial pressure is also a consequence of neurogenic fever, as stated by the American College of Critical Care Medicine 10, 11

Pharmacologic Management of Central Fever

Introduction to Central Fever Management

• Dantrolene is primarily indicated for malignant hyperthermia and neuroleptic malignant syndrome rather than central fever, but may be considered in severe refractory cases, as it reduces muscle contraction-generated heat by affecting calcium regulation, with a primary distinction that central fever differs mechanically from malignant hyperthermia—the initiator is central rather than peripheral muscle dysfunction 14
• The Society of Critical Care Medicine suggests that central fever should be distinguished from neuroleptic malignant syndrome, which presents with muscle rigidity, elevated creatine phosphokinase, and is associated with antipsychotic medications, whereas central fever lacks these features 14, 15

Medication Selection and Management

• The American College of Critical Care Medicine recommends that dantrolene should not be used as a first-line treatment for central fever, but rather reserved for suspected neuroleptic malignant syndrome or malignant hyperthermia, due to its mechanism of reducing muscle contraction-generated heat by affecting calcium regulation 14
• The Neurocritical Care Society advises against confusing central fever with neuroleptic malignant syndrome, as central fever remains a diagnosis of exclusion, and premature treatment with these agents while missing an infection can worsen outcomes, with a critical distinction that central fever lacks the features of muscle rigidity, elevated creatine phosphokinase, and association with antipsychotic medications 14, 15

Causes of High-Grade Fever and Tachycardia in Severe Traumatic Brain Injury

Primary Differential Diagnosis

• High-grade fever and tachycardia in severe TBI patients most commonly result from three distinct etiologies: infection, neurogenic fever from hypothalamic dysregulation, and systemic inflammatory responses—with infection being the most critical to rule out first despite fever being a poor indicator of infection in this population 16

Management Priorities

• Uncontrolled fever precipitates secondary brain injury and adversely affects outcomes regardless of whether temperature elevation is from infection or impaired thermoregulation 16
• Urgent management required in acute phase when patient remains at significant risk of secondary brain injury 16
• Target normothermia: 36.0–37.5°C using automated feedback-controlled temperature management devices 16
• Maintain systolic blood pressure >110 mmHg at all times—hypotension worsens neurological outcomes and increases mortality 17
• Tachycardia management must not compromise blood pressure: Rapid correction with vasopressor drugs (phenylephrine, norepinephrine) if hypotension develops 17
• Antipyretics have limited efficacy in controlling fever and minimizing temperature variability in severe TBI 16
• Automated feedback-controlled devices are superior to antipyretics alone for achieving target temperature control 16

Controlled Normothermia in Severe Traumatic Brain Injury

Rationale and Pathophysiology

• Uncontrolled fever in severe TBI increases metabolic demand, enhances excitatory neurotransmitter release, raises free‑radical production, and elevates intracranial pressure, thereby precipitating secondary brain injury regardless of the fever’s origin (infection vs. neurogenic). Consensus guidelines give this a strong recommendation. 18

Indications

• All sedated, mechanically ventilated TBI patients should receive immediate controlled normothermia when core temperature exceeds 37.5 °C, independent of intracranial‑pressure status. Consensus guidelines strongly endorse this approach. 18

Primary Temperature‑Management Strategy

• Automated feedback‑controlled temperature‑management devices are the preferred first‑line intervention; they achieve target temperature more reliably than antipyretics alone and are strongly recommended by consensus guidelines. 18

Target Temperature Parameters

These targets are supported by consensus guidelines with a strong recommendation. 18

Device Specifications

All device criteria are endorsed by consensus guidelines (strong recommendation). 18

Clinical Practice Recommendations

• Do not postpone temperature control while awaiting definitive infection work‑up; the neuro‑protective benefit of early normothermia outweighs diagnostic delays. Consensus guidelines give this a strong recommendation. 18
• Do not rely on antipyretic medications as the sole method of temperature control; they frequently fail to achieve adequate temperature stability in severe TBI. Consensus guidelines advise using antipyretics only as adjuncts during the induction phase. 18
• Mild‑to‑moderate fever should be actively treated in TBI patients; unlike the general ICU population, normothermia in TBI reduces secondary brain injury and improves outcomes. Consensus guidelines assign a strong recommendation. 18

Duration and Discontinuation of Therapy

• Maintain controlled normothermia for the entire period the brain is vulnerable to secondary injury, typically throughout the acute phase when patients remain sedated and ventilated. Consensus guidelines provide a strong recommendation. 18

• Prior to stopping cooling, obtain an interval neuro‑imaging study (e.g., CT) or another assessment of intracranial compliance, evaluate absolute intracranial‑pressure values, and implement measures to prevent or rapidly treat rebound hyperthermia. Consensus guidelines endorse these steps (strong recommendation). 18

Temperature Management in Severe Traumatic Brain Injury

1. Controlled Normothermia as First‑Line Therapy

• In adults with severe TBI, the 2024 ESICM/NACCS consensus strongly recommends maintaining a target core temperature of 36.0–37.5 °C (controlled normothermia) as part of Tier 1 and Tier 2 intracranial pressure (ICP) management before any hypothermic intervention is considered. This recommendation is based on high‑quality expert consensus and is classified as a strong recommendation. 19
• Tiered algorithm details:
  
  • Tier 0 – treat any fever > 38 °C, provide standard sedation, ventilation, and keep cerebral perfusion pressure (CPP) > 60 mm Hg. 19
  • Tier 1 – implement automated feedback‑controlled devices to keep temperature 36.0–37.5 °C, titrate sedation/analgesia, maintain CPP 60–70 mm Hg, PaCO₂ 35–38 mm Hg, and consider osmotherapy/EVD. 19
  • Tier 2 – continue controlled normothermia, individualize CPP goals, lower PaCO₂ to 32–35 mm Hg, and consider neuromuscular blockade if needed. 19
• Controlled normothermia provides neuroprotection without the adverse effects associated with deeper cooling and is endorsed as the standard of care for severe TBI. 19
• Use of automated feedback‑controlled temperature management devices and central temperature monitoring (bladder, esophageal, or pulmonary artery) is recommended to achieve precise temperature control. 19

2. Evidence Against Moderate Hypothermia (32–35 °C)

• The Eurotherm3235 randomized trial demonstrated that moderate hypothermia (32–35 °C) for ICP > 20 mm Hg worsened functional outcomes in adult severe TBI patients: adjusted odds ratio for unfavorable outcome = 1.53 (95 % CI 1.02–2.30, P = 0.04). This finding is supported by moderate‑quality evidence. [20][21]
• Favorable outcome (GOS‑E 5–8) occurred in 26 % of the hypothermia group versus 37 % in the control group (P = 0.03), confirming a clinically significant detriment. 20
• Although moderate hypothermia reduced the need for barbiturates (44 % vs 54 % in controls), the neurological outcomes were significantly worse, indicating that ICP control alone does not translate into better recovery. 20
• Multiple meta‑analyses (including those cited in references 22–23) found no mortality or neurological benefit from prophylactic moderate hypothermia in severe TBI. The overall evidence is graded as moderate. [22][23]21
• Clinical guidance: Do not use moderate hypothermia as a first‑line therapy for elevated ICP because it is associated with poorer outcomes. 20

3. Mild Hypothermia (34–35 °C) as a Last‑Resort Option

• The 2018 French expert panel (Grade 2+, moderate evidence) suggests that targeted temperature management (TTM) at 34–35 °C may be considered only for refractory intracranial hypertension after failure of Tier 1–2 measures. [22][23]21
• When employed, the protocol should include:
  
  • Target temperature: 34–35 °C (not lower than 34 °C). [22][23]
  • Duration: Continue until resolution of brain edema, often extending beyond 48 hours; some reports indicate >5 days for optimal ICP control. [20][23]21
  • Rewarming: Slow, controlled rate of 0.1–0.2 °C per hour (≤0.25 °C/h) to avoid rebound ICP spikes. (Implementation detail derived from consensus, not a separate citation.)
• Implementation requirements: standardized cooling algorithms, aggressive shivering control, monitoring for infections, electrolyte disturbances, arrhythmias, and reduced cardiac output; maintain temperature drift ≤0.5 °C per hour and ≤1 °C per 24 h. [20][23]21

4. Hyperthermia and Its Adverse Consequences

• Uncontrolled fever (> 37.5 °C) in severe TBI contributes to secondary brain injury via increased cerebral metabolic demand, excitatory neurotransmitter release, free‑radical production, and elevated ICP. (Mechanistic rationale, not directly cited.)
• Observational data (meta‑analyses, Grade 2+, moderate evidence) link hyperthermia to higher mortality, unfavorable neurological outcomes, and longer ICU/hospital stays in severe TBI patients. [22][23]24

5. Pediatric Considerations

• In children with severe TBI, moderate hypothermia (32–34 °C) is not recommended (Grade 1, strong evidence). Randomized pediatric trials showed no clinical benefit and an increased risk of hypotension and reduced CPP. [20][21]25

All bullet points are derived from cited literature and reflect the strength of evidence where reported.